Early Salvage Radiotherapy for Biochemical Recurrence After Prostatectomy

Initiation of SRT at prostate-specific antigen levels of ≤0.5 ng/mL was associated with improved outcomes.

Detectable prostate-specific antigen (PSA) following radical prostatectomy for prostate cancer is seen in 25% to 35% of patients. Such biochemical recurrence represents a clinical dilemma, as it potentially represents either local or local and systemic disease. Prospective evidence supports the use of salvage radiotherapy (SRT) in this setting, but when to administer SRT is unclear.

Now, investigators at a single academic center have assessed outcomes over a 25-year period in 1106 prostate cancer patients who had detectable PSA (≥0.1 ng/mL) after radical prostatectomy and were treated with SRT. Patients were stratified by pre-SRT PSA levels of ≤0.5 and ≥0.5 ng/mL.

At median follow-up of 8.9 years, 54% of patients had experienced biochemical r…

Reviewing Author

Robert Dreicer, MD, MS, FACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, FACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Early Salvage Radiotherapy for Biochemical Recurrence After Prostatectomy

Topics

Reviewing Author